As GScore increases, glioma patients tend to have higher WHO grades and shorter overall survival (OS) and are more likely to exhibit isocitrate dehydrogenase (IDH) wildtype status and MGMT promoter unmethylation, which all indicate that elevated GScore is associated with poor clinical outcomes (Fig. 1B). The gene discussed is IDH3A; the disease is central nervous system cancer.